Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

The Italian Society of Infectious and Tropical Diseases (SIMIT) of the Technical Health Committee, Ministry of Health (Sections L and M) of Italy have supported recommendations for the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. This publication summarizes the latest updates to the 2016 version of the Italian Guidelines for the management of HIV-1 infected patients and the use of antiretroviral drugs. In particular, new recommendations were released concerning the following topics: estimate of the HIV continuum of care in Italy, optimal timing and preferred drug combinations for starting antiretroviral therapy, treatment optimization, and pre-exposure prophilaxis (PrEP). For a complete review of clinical and therapeutic relevant topics we refer the reader to the extended version of the Guidelines.

[1]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[2]  J. De La Torre,et al.  Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study , 2018, Journal of the International Association of Providers of AIDS Care.

[3]  A. Antinori,et al.  Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL , 2017, Infection.

[4]  A. De Luca,et al.  Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. , 2016, The Journal of infection.

[5]  G. Barbarini,et al.  Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort , 2016, PloS one.

[6]  R. Maserati,et al.  Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). , 2016, The new microbiologica.

[7]  R. Grant,et al.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations , 2016, AIDS.

[8]  Barbara Suligoi,et al.  How many people are living with undiagnosed HIV infection? An estimate for Italy, based on surveillance data , 2016, AIDS (London).

[9]  K. Lichtenstein,et al.  Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study , 2016, Journal of acquired immune deficiency syndromes.

[10]  B. Spire,et al.  Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial , 2016, AIDS care.

[11]  L. Calza,et al.  Dual Raltegravir–Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors , 2016, HIV clinical trials.

[12]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[13]  J. van Lunzen,et al.  Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study , 2016, AIDS.

[14]  D. Wohl,et al.  The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir† , 2015, HIV medicine.

[15]  G. d’Ettorre,et al.  Simplification to atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir+2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial , 2016 .

[16]  S. Hammer,et al.  Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. , 2016, Journal of acquired immune deficiency syndromes.

[17]  J. van Lunzen,et al.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. , 2016, The Lancet. Infectious diseases.

[18]  M. Peeters,et al.  Dual therapy with a boosted protease inhibitor plus lamivudine is an effective maintenance strategy in patients on second-line antiretroviral therapy in Africa : the ANRS 12286/MOBIDIP trial , 2016 .

[19]  H. Jessen,et al.  HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans , 2016, Infection.

[20]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[21]  A. Antinori,et al.  Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort. , 2015, Journal of acquired immune deficiency syndromes.

[22]  O. Turriziani,et al.  Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization. , 2015, The new microbiologica.

[23]  A. Winston,et al.  Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial , 2015, The lancet. HIV.

[24]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[25]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[26]  M. Saag,et al.  Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study , 2015, Journal of Acquired Immune Deficiency Syndromes.

[27]  F. Antunes,et al.  Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results , 2015, Journal of acquired immune deficiency syndromes.

[28]  J. Navarro,et al.  Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. , 2015, The Lancet. Infectious diseases.

[29]  D. Podzamczer,et al.  Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. , 2015, The Lancet. Infectious diseases.

[30]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[31]  R. Speck,et al.  Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and T , 2015, The Patient - Patient-Centered Outcomes Research.

[32]  K. Lichtenstein,et al.  P029: Safety of tenofovir alafenamide in renal impairment , 2015 .

[33]  A. Lazzarin,et al.  Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy , 2015, Journal of the International AIDS Society.

[34]  F. Dabis,et al.  Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014 , 2015, Open forum infectious diseases.

[35]  K. Tashima,et al.  Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial , 2014, AIDS Research and Therapy.

[36]  A. Antinori,et al.  Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial , 2014, The Lancet.

[37]  A. Antinori,et al.  Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort , 2014, Journal of the International AIDS Society.

[38]  David W. Haas,et al.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. , 2014, Annals of internal medicine.

[39]  F. Raffi,et al.  Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. , 2014, The Journal of antimicrobial chemotherapy.

[40]  A. d’Arminio Monforte,et al.  Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. , 2014, The new microbiologica.

[41]  M. Timmers,et al.  Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers , 2014, Journal of clinical pharmacology.

[42]  S. Piscitelli,et al.  Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food , 2014, Journal of acquired immune deficiency syndromes.

[43]  K. Stanecki,et al.  Estimates of the Number of People Living with HIV in Italy , 2014, BioMed research international.

[44]  K. White,et al.  Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b , 2014, The Lancet. Infectious diseases.

[45]  K. White,et al.  Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inf , 2014, The Lancet. Infectious diseases.

[46]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study , 2014, The Lancet.

[47]  A. Waldman,et al.  Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. , 2014, The Journal of antimicrobial chemotherapy.

[48]  K. White,et al.  Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults , 2014, AIDS.

[49]  A. Lazzarin,et al.  Durability of Lopinavir/Ritonavir Monotherapy in Individuals with Viral Load ≦50 Copies/Ml in an Observational Setting , 2014, Antiviral therapy.

[50]  K. White,et al.  A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results , 2014, Journal of acquired immune deficiency syndromes.

[51]  K. White,et al.  A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. , 2014, Journal of acquired immune deficiency syndromes.

[52]  A. Winston,et al.  Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials , 2014, Journal of the International AIDS Society.

[53]  A. d’Arminio Monforte,et al.  Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study , 2014, Journal of the International AIDS Society.

[54]  D. Carey.  Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study , 2014, Journal of the International AIDS Society.

[55]  B. Gazzard,et al.  Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants , 2014, AIDS.

[56]  Jias Production.  International Congress of Drug Therapy in HIV Infection 2-6 November 2014, Glasgow, UK , 2014, Journal of the International AIDS Society.

[57]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[58]  J. Gatell,et al.  Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[59]  K. White,et al.  Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens , 2013, HIV clinical trials.

[60]  F. Antunes,et al.  Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. , 2013, The Journal of infectious diseases.

[61]  M. Di Nicola,et al.  Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy , 2013, Journal of medical virology.

[62]  Y. Yazdanpanah,et al.  Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK , 2013, Journal of acquired immune deficiency syndromes.

[63]  M. Bloch,et al.  Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies , 2013, HIV clinical trials.

[64]  Clare Brennan,et al.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.

[65]  C. Orkin,et al.  Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial , 2013, HIV medicine.

[66]  D. Ward,et al.  ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine , 2012, HIV clinical trials.

[67]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial , 2012, The Lancet.

[68]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.

[69]  B. Clotet,et al.  Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials , 2012, Journal of acquired immune deficiency syndromes.

[70]  C. Katlama,et al.  Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. , 2012, The Journal of antimicrobial chemotherapy.

[71]  D. Podzamczer,et al.  Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy , 2012, AIDS.

[72]  J. Stockman,et al.  Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men , 2012 .

[73]  D. Katzenstein,et al.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.

[74]  R. Kuchenbecker,et al.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. , 2011, Annals of internal medicine.

[75]  J. Montaner,et al.  Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen , 2011, PloS one.

[76]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[77]  F. Antunes,et al.  Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial , 2011, Antiviral therapy.

[78]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. , 2011, The new microbiologica.

[79]  A. Lazzarin,et al.  Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen , 2010, Antiviral therapy.

[80]  H. Günthard,et al.  Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir , 2010, AIDS.

[81]  D. Podzamczer,et al.  Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study , 2010, Journal of acquired immune deficiency syndromes.

[82]  J. Absalon,et al.  Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study , 2010, Journal of acquired immune deficiency syndromes.

[83]  D. Cooper,et al.  Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.

[84]  Christine Gutmanna,et al.  Randomized controlled stu dy demonstrating failure of LPV / r monotherapy in HIV : the role of compartment and CD 4-nadir , 2010 .

[85]  Lynne Peeples,et al.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.

[86]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[87]  D. Podzamczer,et al.  Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study , 2009, Journal of acquired immune deficiency syndromes.

[88]  D. Podzamczer,et al.  Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression , 2009, Antiviral therapy.

[89]  C. Boucher,et al.  HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review , 2009, AIDS.

[90]  J. van Lunzen,et al.  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 , 2008, AIDS.

[91]  M. King,et al.  A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. , 2008, The Journal of infectious diseases.

[92]  Lynne Peeples,et al.  Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.

[93]  B. Gazzard,et al.  Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis , 2008, Journal of acquired immune deficiency syndromes.

[94]  A. Sönnerborg,et al.  Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. , 2007, Journal of acquired immune deficiency syndromes.

[95]  C. Leen,et al.  Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  D. Podzamczer,et al.  Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients , 2007, AIDS.

[97]  J. Mellors,et al.  Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. , 2006, JAMA.

[98]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[99]  Steve A Castillo,et al.  Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.